Ipilimumab (anti-CTLA-4), for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to CTLA-4/CD152, >95% (SDS-PAGE&SEC), high purity, Human IgG1, Antibody of cytotoxic T-lymphocyte-associated protein 4 (CD152)
Ipilimumab (anti-CTLA-4), for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to CTLA-4/CD152, >95% (SDS-PAGE&SEC), high purity, Human IgG1, Antibody of cytotoxic T-lymphocyte-associated protein 4 (CD152)
Ipilimumab (anti-CTLA-4), for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to CTLA-4/CD152, >95% (SDS-PAGE&SEC), high purity, Human IgG1
Antibody of cytotoxic T-lymphocyte-associated protein 4 (CD152)
Product Description
Ipilimumab (anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4; It is also an immune checkpoint inhibitor. Purity>95% (SDS-PAGE&SEC) Endotoxin Level< 0.01EU/μg
Product Properties
Antibody Type
Primary antibody
Clonality
Recombinant
Isotype
Human IgG1
Light Chain Type
kappa
SDS-PAGE
26.9 kDa (Light Chain) & 52.7 kDa (Heavy Chain), under reducing conditions; 176.3 kDa, under non-reducing conditions.
Purification Method
Protein A purified
Purity
>95% (SDS-PAGE&SEC)
Source
CHO supernatant
Form
Liquid
Concentration
Lot by Lot
Storage Temp
Store at -80°C,Avoid repeated freezing and thawing
Shipped In
Ice chest + Ice pads
Stability And Storage
Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS
477202-00-9
Images
Ipilimumab (anti-CTLA-4) (I411993) - ELISA Immobilized Hu-CTLA-4-His at 2 μg/mL can bind Ipilimumab (anti-CTLA-4) (I411993) with the EC₅₀ of 6.69 ng/mL.
Ipilimumab (anti-CTLA-4) (I411993) - SEC The purity of Ipilimumab (anti-CTLA-4) (I411993) is more than 95% verified by HPLC.
Ipilimumab (anti-CTLA-4) (I411993) - ELISA Immobilized Recombinant Human CTLA4 protein (rp176276) at 1.0 μg/mL can bind Ipilimumab (anti-CTLA-4) (I411993) with the EC₅₀ of 19.03 ng/mL.
Associated Targets
CTLA4Tclin Cytotoxic T-lymphocyte protein 4 0 Activities
1.Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS et al.. (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.. N Engl J Med, 372 (21):(2006-17). [PMID:25891304]
2.Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P et al.. (2015) Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.. N Engl J Med, 373 (1):(23-34). [PMID:26027431]
3.Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S et al.. (2018) Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.. N Engl J Med, 378 (14):(1277-1290). [PMID:29562145]
Solution Calculators
Molarity Calculator
Determine the necessary mass, volume, or concentration for preparing a solution.
Dilution Calculator
Determine the dilution needed to prepare a stock solution.
ZJ24F0404213